Connect Biopharma Holdings Limited — Form 6-K Summary
Business context and reporting period
This Form 6-K, furnished December 2, 2022, reports an exchange-listing compliance matter for Connect Biopharma Holdings Limited, a foreign private issuer. The report covers the month of November 2022 and was signed by Chief Financial Officer Steven Chan.
Financial metrics and liquidity
The filing does not provide financial statements or clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material changes and listing compliance
- On November 28, 2022, Nasdaq notified the Company that its American Depositary Shares had closed below the $1.00 minimum bid-price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
- The Company received an initial 180-calendar-day compliance period ending May 29, 2023, the first business day after the applicable period.
- Compliance would be restored if the ADS bid price closed at or above $1.00 for at least 10 consecutive business days before the deadline.
- The Nasdaq notice had no immediate effect on the listing or trading of the ADSs, which continued to trade on the Nasdaq Global Market under the symbol CNTB.
Outlook, contingencies, and risks
- Management stated that it would monitor the ADS bid price and consider available options if the price did not appear likely to recover by May 29, 2023.
- If compliance was not regained, the Company might have been eligible for an additional 180-day period, subject to transferring to the Nasdaq Capital Market and satisfying applicable market-value and other initial-listing requirements.
- If Nasdaq determined that the deficiency could not be cured or that the Company was otherwise ineligible, the ADSs could become subject to delisting. The Company would have an appeal right, but there was no assurance that continued listing would be granted.
Key facts for investors to verify
- Whether the ADS price recovered to at least $1.00 for the required 10 consecutive business days before May 29, 2023.
- Whether Nasdaq granted any additional compliance period, required a market transfer, or initiated delisting proceedings.
- Any subsequent financing, reverse stock split, corporate action, or other measure affecting the ADS price or Nasdaq listing status.
- Current financial condition and liquidity, which are not disclosed in this Form 6-K.